c-Kit
SCFR; CD117
c-Kit (Mast/stem cell growth factor receptor, SCFR or CD117) is a proteinthat in humans is encoded by the KIT gene. c-Kit (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. c-Kit is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. c-Kit is a receptor tyrosine kinase type III, which binds to stem cell factor. When c-Kit binds to stem cell factor (SCF) it forms adimer that activates its intrinsic tyrosine kinase activity, that in turn phosphorylates and activates signal transduction molecules that propagate the signal in the cell. Signalling through c-Kit plays a role in cell survival, proliferation, and differentiation.
All Product Categories
-
c-Kit Produits associés (206)
Produits associés (206)
-
Protéines Recombinantes (20)
-
Anticorps (3)
-
AK177
0 ImagesCat. No.: HY-181886AK177 is an allosteric activator of IRE1α ribonuclease, with values of 480 nM and 180 nM against non-phosphorylated and phosphorylated IRE1α, respectively. AK177 promotes IRE1α-mediated cleavage of XBP1 mRNA probe in a concentration-dependent manner and binds stably to its kinase domain. However, AK177 shows poor kinase selectivity, and due to poor membrane permeability at the cellular level, it induces no significant downstream pathway activation or antiproliferative activity.
-
Regorafenib monohydrate (Standard)
0 ImagesSynonyms: BAY 73-4506 monohydrate (Standard)Regorafenib (monohydrate) (Standard) is the analytical standard of Regorafenib (monohydrate). This product is intended for research and analytical applications. Regorafenib (BAY 73-4506) monohydrate is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib monohydrate shows very robust antitumor and antiangiogenic activity.
-
PLX647 dihydrochloride
0 ImagesCat. No.: HY-13838ACAS No.: 1779796-38-1PLX647 dihydrochloride is an orally active, highly specific dual FMS and KIT kinase inhibitor, with IC50s of 28 and 16 nM, reapectively. PLX647 dihydrochloride shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR (IC50s=91 and 130 nM, respectively).
-
GW632046X
0 ImagesCat. No.: HY-160690CAS No.: 681002-67-5GW632046X is a Fluc (Firefly luciferase) inhibitor with an IC50 value of 0.58 µM.
-
c-Kit-IN-14
0 ImagesCat. No.: HY-180653CAS No.: 3041025-49-1
-
c-Kit-IN-13
0 ImagesCat. No.: HY-180652CAS No.: 3041025-10-6
-
Midostaurin-13C6
0 ImagesCat. No.: HY-W751179Synonyms: PKC412-13C6; CGP 41251-13C6Midostaurin-13C6 (PKC412-13C6) is the 13C-labeled Midostaurin (HY-10230). Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM. Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects.
-
BLU-654
0 ImagesCat. No.: HY-182043CAS No.: 2999638-62-7BLU-654 is an orally active antineoplastic agent and KIT inhibitor. BLU-654 is a highly selective inhibitor targeting wild-type KIT, PDGFRβ, and KITV654A over most other kinases in the kinome. BLU-654 exerts sustained antineoplastic activity in KITV654A cell-derived xenograft mouse models. BLU-654 can be used in research related to Imatinib (HY-15463)-resistant gastrointestinal stromal tumors.
-
KIT V559D Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70738KIT (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. KIT is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. KIT V559D is a mutant of KIT. KIT V559D Recombinant Human Active Protein Kinase is a recombinant KIT V559D protein that can be used to study KIT V559D-related functions.
-
KBP-7018 hydrochloride
0 ImagesCat. No.: HY-117873ACAS No.: 1613437-67-4KBP-7018 hydrochloride is an orally active, tyrosine kinase-selective multi-kinase inhibitor with an IC50 value of 10 nM against c-KIT, 7.6 nM against RET, and 25 nM against human PDGFR. KBP-7018 hydrochloride improves survival rates in a mouse model of pulmonary fibrosis. KBP-7018 hydrochloride can be used in research related to idiopathic pulmonary fibrosis.
-
KIT V560G Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70741KIT (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. KIT is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. KIT V560G is a mutant of KIT. KIT V560G Recombinant Human Active Protein Kinase is a recombinant KIT V560G protein that can be used to study KIT V560G-related functions.
-
Toceranib-d8
0 ImagesToceranib-d8 is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors.
-
APcK110
0 ImagesCat. No.: HY-110071CAS No.: 1001083-74-4APcK110 is a potent Kit inhibitor that can be used for the research of acute myeloid leukemia (AML). APcK110 induces AML cell apoptosis.
-
KIT D816V Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70736KIT (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. KIT is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. KIT D816V is a mutant of KIT. KIT D816V Recombinant Human Active Protein Kinase is a recombinant KIT D816V protein that can be used to study KIT D816V-related functions.
-
CDX-0158
0 ImagesCat. No.: HY-P992509Synonyms: NCT02642016; KTN0158CDX-0158 (NCT02642016; KTN0158) is a humanized anti-c-Kit/CD117 IgG1κ monoclonal antibody. CDX-0158 effectively blocks the SCF-KIT signaling pathway and inhibits mast cell activation, but due to the retention of wild-type IgG1 Fc, it can induce mast cell degranulation through FcyR cross-linking, resulting in obvious infusion reactions. CDX-0158 can be used in research related to advanced refractory gastrointestinal stromal tumors.
-
KIT D816H Recombinant Human Active Protein Kinase
0 ImagesCat. No.: HY-E70735KIT (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. KIT is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. KIT D816H is a mutant of KIT. KIT D816H Recombinant Human Active Protein Kinase is a recombinant KIT D816H protein that can be used to study KIT D816H-related functions.
-
JI6
0 ImagesCat. No.: HY-18949CAS No.: 856436-16-3
-
Multi-kinase-IN-2
0 ImagesCat. No.: HY-150026CAS No.: 2095628-21-8Multi-kinase-IN-2 (compound 7h) is an orally active and potent angiokinase inhibitor. Multi-kinase-IN-2 exhibits excellent inhibitory activity against angiokinases including VEGFR-1/2/3, PDGFRα/β, and FGFR-1, as well as LYN and c-KIT kinases. Multi-kinase-IN-2 significantly attenuates phosphorylation of AKT and ERK proteins. Multi-kinase-IN-2 induces cell apoptosis. Multi-kinase-IN-2 shows anticancer activity.
-
KI-328
0 ImagesCat. No.: HY-121708CAS No.: 930089-25-1KI-328 is a novel inhibitor targeting KIT kinase that has selective activity against some KIT mutant kinases commonly found in acute myeloid leukemia (AML). KI-328 showed specificity for KIT kinase in in vitro kinase assays and inhibited the growth of wild-type (Wt) and mutant KIT-expressing cells, but had lower activity against D816V-KIT. Comparative analysis of the inhibitory effects of several potent KIT inhibitors on the growth of multiple mutant KIT-expressing cells showed that the multi-kinase inhibitors had comparable activity against D816V-KIT as against other mutant KITs; however, heat shock protein 90 (HSP90) inhibitors showed significant activity against D816V-KIT, inhibiting the growth of D816V-KIT-expressing cells at concentrations that did not affect the growth of other mutant KIT-expressing cells. These results suggest that potent KIT inhibitors have different activities against different types of KIT mutant kinases. Therefore, in clinical development, KIT inhibitors need to validate their activity against multiple types of KIT mutant kinases.
